Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre Vascular's gross profit for the
three
months ended in Mar. 2026 was $48.4 Mil. LeMaitre Vascular's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $185.5 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
LeMaitre Vascular had a gross margin of 72.72% for the quarter that ended in Mar. 2026 => Durable competitive advantage
LeMaitre Vascular Gross Profit Related Terms
LeMaitre Vascular Gross Profit Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Gross Profit distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $185.5 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
LeMaitre Vascular (LMAT) has a Gross Profit of $185.5 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on LeMaitre Vascular and its competitors.
Is LeMaitre Vascular's Gross Profit too high?
LeMaitre Vascular's current Gross Profit is $185.5 Mil. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Gross Profit compare to PLSE and XRAY?
LeMaitre Vascular's Gross Profit of $185.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on LeMaitre Vascular and its competitors. LeMaitre Vascular's current Gross Profit is $185.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Gross Profit is $185.5 Mil. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Gross Profit is $185.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Gross Profit: $185.5 Mil
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
